A groundbreaking male contraceptive gel, NES/T, containing segesterone acetate and testosterone, shows promising results in suppressing sperm production faster than previous methods.

In a recent phase 2b clinical trial with 222 men, most participants reached the effective sperm count threshold of 1 million or fewer sperm per milliliter of semen by week 15 of treatment.

Suppression of sperm production was achieved in less than 8 weeks on average.

Plans for a Phase III trial and commercial partnership are in progress to further evaluate the gel's safety, effectiveness, and reversibility.

The addition of segesterone acetate to testosterone lowers the dose needed for sperm suppression and maintains normal sexual function, potentially increasing the attractiveness of the contraceptive to potential users.

Despite growing interest in male birth control, securing financial support from investors is a significant obstacle in bringing these new methods to market.

The conversation around male contraception needs to shift to view it as an essential aspect of women's health and contraception to drive progress in this area.